| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/10/2008 | WO2008040934A1 Hdac inhibitors |
| 04/10/2008 | WO2008040833A1 Method for obtaining bicyclic peptides |
| 04/10/2008 | WO2008040547A1 Substituted indeno[1,2-b]indole derivatives as novel inhibitors of protein kinase ck2 and their use as tumour therapeutic agents, cytostatics and diagnostic aids |
| 04/10/2008 | WO2008040362A2 Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| 04/10/2008 | WO2008040208A1 (2z)-2-(3,4-dihydroxybenzylidene)-1-benzofuran-3(2h)-one in manufacture of medicaments for treating cancers |
| 04/10/2008 | WO2008040190A1 Small peptides for anti-angiogenesis and use thereof |
| 04/10/2008 | WO2008040149A1 Composition and method for treating immune-mediated skin disorders |
| 04/10/2008 | WO2008028141A3 Raf inhibitor compounds and methods of use thereof |
| 04/10/2008 | WO2008027523A3 Salts of benzimidazolyl pyridyl ethers and formulations thereof |
| 04/10/2008 | WO2008021364A3 Triazole compounds that modulate hsp90 activity |
| 04/10/2008 | WO2008020027A3 2,5-dihydroxybenzene compounds for the treatment of skin cancer |
| 04/10/2008 | WO2008016547A3 Aurora kinase inhibitors from an encoded small molecule library |
| 04/10/2008 | WO2008015578A3 Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
| 04/10/2008 | WO2008012110A3 Annellated pyrrole compounds for cancer management |
| 04/10/2008 | WO2008011094A3 Cytokine induction of selectin ligands on cells |
| 04/10/2008 | WO2007149451B1 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
| 04/10/2008 | WO2007115289A3 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 04/10/2008 | WO2007107774A3 Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer |
| 04/10/2008 | WO2007107161A3 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| 04/10/2008 | WO2007089445A3 Ang2 and vegf inhibitor combinations |
| 04/10/2008 | WO2007048985A3 Substance for restoring normal co-expression and interaction between lox and nrage proteins |
| 04/10/2008 | WO2007015280A8 Benzodiazepine derivatives and uses thereof in medical field |
| 04/10/2008 | US20080086000 Prostaglandin reductase |
| 04/10/2008 | US20080085995 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/10/2008 | US20080085929 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same |
| 04/10/2008 | US20080085923 Thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer; use with other drugs such as aspirin, clodipogrel, prasugrel, cangrelor, Fragmin; himbacine derivatives |
| 04/10/2008 | US20080085909 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one |
| 04/10/2008 | US20080085904 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant |
| 04/10/2008 | US20080085902 Prevention or treatment of proliferative diseases by administering a VEGF inhibitor compound such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and one or more chemotherapeutic agents such as N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; cancer |
| 04/10/2008 | US20080085898 And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection |
| 04/10/2008 | US20080085897 Inhibitors of cyclic guanosine monophosphate-metabolizing phosphodiesterases (cGMP PDE); cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia; 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f]-[1,2,4]triazin-4-one for example |
| 04/10/2008 | US20080085896 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications |
| 04/10/2008 | US20080085893 N-Hydroxy (2S)-2-hydroxy phenyl or heteroaryl sulfonamide derivatives; for example, N-Hydroxy (2S)-2-hydroxy-3-{N-[4-(4- chlorophenoxy)phenyl], N- methanesulfonylamino}propionamide; for treating disorders related to matrix metalloproteases, particularly useful for treating strokes; |
| 04/10/2008 | US20080085891 Asthma and allergic inflammation modulators |
| 04/10/2008 | US20080085890 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof |
| 04/10/2008 | US20080085882 Chemotherapeutic agent and an antitumor modulator of bis(3-amino-1-alkanolato-)-di- mu -[halo/hydroxyl/thiocyanato/nitro]-di-Copper complex |
| 04/10/2008 | US20080085879 Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation |
| 04/10/2008 | US20080085875 Crystalline forms of 11ss-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17a-pregna-4,9-dien-3-one |
| 04/10/2008 | US20080085871 Polysaccharide component protects the 5-FU from absorption in the upper gastrointestinal tract, delivers the 5-FU to the colorectal area |
| 04/10/2008 | US20080085861 Gas1 polypeptides |
| 04/10/2008 | US20080085859 Drug Promoting Ceramide Transport, Base Sequence for Producing the Drug, Method of Measuring Activity of Promoting Ceramide Release and Method of Measuring Activity of Promoting Intermembrane Ceramide Transfer |
| 04/10/2008 | US20080085857 conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 |
| 04/10/2008 | US20080085853 nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; |
| 04/10/2008 | US20080085328 Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof |
| 04/10/2008 | US20080085283 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| 04/10/2008 | US20080085278 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 04/10/2008 | US20080085271 Methods of preventing or treating cell-migration mediated conditions or diseases |
| 04/10/2008 | US20080085244 comparing levels with untreated ovariectomized animal determining amount of an estrogen to reduce amyloid peptides in brain of an animal without affecting soluble APP level; administering test compound to an ovariectomized non-human animal; beta.17-estradiol reversed ovx-associated levels; Alzheimer's |
| 04/10/2008 | US20080085243 Molecular markers for determining taxane responsiveness |
| 04/10/2008 | US20080085242 modified biodegradable branched chitosans effectively complexed with nucleic acids |
| 04/10/2008 | US20080085239 complex with radioisotope; anticancer radiopharmaceutical; diagnosis of tumors |
| 04/10/2008 | DE102006047231A1 Substituierte Indeno[1,2-b]indolderivate als neue Hemmstoffe der Protein Kinase CK2 und ihre Verwendung als Tumor Therapeutika, Cytostatika und Diagnostika Substituted indeno [1,2-b] indole derivatives as new inhibitors of protein kinase CK2 and their use as antitumor agents, cytostatic agents and diagnostic agents |
| 04/10/2008 | DE10066235B4 Targeted inhibition of gene expression by administration of double stranded oligoribonucleotide to a cell, useful for treating humans, animals and plants against viral infection |
| 04/10/2008 | CA2665468A1 Substituted indeno[1,2-b]indole derivatives as novel inhibitors of protein kinase ck2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids |
| 04/10/2008 | CA2665428A1 Hdac inhibitors |
| 04/10/2008 | CA2665387A1 Grp78 as a predictor of responsiveness to therapeutic agents |
| 04/10/2008 | CA2665356A1 Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| 04/10/2008 | CA2665202A1 Compounds and methods |
| 04/10/2008 | CA2665141A1 Composition comprising crustacean gastrolith components and its use |
| 04/10/2008 | CA2665105A1 Injectable depot composition and its' process of preparation |
| 04/10/2008 | CA2664852A1 High-molecular weight conjugate of resorcinol derivatives |
| 04/10/2008 | CA2664842A1 Arginine derivatives with np-i antagonistic activity |
| 04/10/2008 | CA2664738A1 Compositions and methods for diagnosing and treating cancer |
| 04/10/2008 | CA2664567A1 Tumor immunity |
| 04/10/2008 | CA2664356A1 Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor |
| 04/10/2008 | CA2664158A1 Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 04/10/2008 | CA2663856A1 Jak-2 modulators and methods of use |
| 04/10/2008 | CA2564154A1 Immunocan |
| 04/09/2008 | EP1908826A1 Prostate cancer related protein derived peptide which is a peptide vaccine candidate for prostate cancer patients with hla-a3 supertype alleles |
| 04/09/2008 | EP1908825A1 ANTIBODY DIRECTED AGAINST PAP2a AND USE THEREOF FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| 04/09/2008 | EP1908823A1 Component of bromelain |
| 04/09/2008 | EP1908781A2 Modulation of immune response and methods based thereon |
| 04/09/2008 | EP1908780A1 Novel chimeric proteins and methods for using the same |
| 04/09/2008 | EP1908751A1 N-hydroxy benzamides with antitumour activity |
| 04/09/2008 | EP1908479A2 Anti-p53 Antibodies |
| 04/09/2008 | EP1908478A1 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation |
| 04/09/2008 | EP1908477A2 Combination of temozolomide and pegylated interferon-alpha for treating cancer |
| 04/09/2008 | EP1908475A1 Use of anti-prolactin agents to treat cancer |
| 04/09/2008 | EP1908474A2 Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 04/09/2008 | EP1908466A1 Substituted propanamide derivative and pharmaceutical composition containing the same |
| 04/09/2008 | EP1908459A1 Composition for prevention of cancer |
| 04/09/2008 | EP1907572A2 Prostate stem cell markers |
| 04/09/2008 | EP1907426A2 Novel anti-igf-ir antibodies and uses thereof |
| 04/09/2008 | EP1907399A1 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands |
| 04/09/2008 | EP1907385A2 Compounds |
| 04/09/2008 | EP1907379A1 Crystalline forms of (2r-trans)-6-chloro-5ýý4-ý(4-fluorophenyl)methyl¨-2,5-dimethyl-1-piperazinyl¨carbonyl¨-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride |
| 04/09/2008 | EP1907362A1 Amide derivatives as kinase inhibitors |
| 04/09/2008 | EP1907009A1 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
| 04/09/2008 | EP1906997A2 Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| 04/09/2008 | EP1906977A1 Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
| 04/09/2008 | EP1906955A2 Use of thiazole derivatives and analogues in the treatment of cancer |
| 04/09/2008 | EP1906950A2 Ansamycin formulations and methods of use thereof |
| 04/09/2008 | EP1906948A2 Treatment of cancer |
| 04/09/2008 | EP1906944A1 Schisandrin b preparation |
| 04/09/2008 | EP1906924A1 Bone marrow-directing drug delivery materials and their applications |
| 04/09/2008 | EP1414444B1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 04/09/2008 | EP1228095B1 Modified gp100 and uses thereof |
| 04/09/2008 | EP1173767B1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 04/09/2008 | EP1140964B1 Connective tissue growth factor (ctgf) fragment |
| 04/09/2008 | EP1100892B1 Use of prohibitin rna in treatment of cancer |